<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38543849</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>21</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>A Cocktail of Lipid Nanoparticle-mRNA Vaccines Broaden Immune Responses against β-Coronaviruses in a Murine Model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">484</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16030484</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome (SARS)-coronavirus (CoV), Middle Eastern respiratory syndrome (MERS)-CoV, and SARS-CoV-2 have seriously threatened human life in the 21st century. Emerging and re-emerging β-coronaviruses after the coronavirus disease 2019 (COVID-19) epidemic remain possible highly pathogenic agents that can endanger human health. Thus, pan-β-coronavirus vaccine strategies to combat the upcoming dangers are urgently needed. In this study, four LNP-mRNA vaccines, named O, D, S, and M, targeting the spike protein of SARS-CoV-2 Omicron, Delta, SARS-CoV, and MERS-CoV, respectively, were synthesized and characterized for purity and integrity. All four LNP-mRNAs induced effective cellular and humoral immune responses against the corresponding spike protein antigens in mice. Furthermore, LNP-mRNA S and D induced neutralizing antibodies against SARS-CoV and SARS-CoV-2, which failed to cross-react with MERS-CoV. Subsequent evaluation of sequential and cocktail immunizations with LNP-mRNA O, D, S, and M effectively elicited broad immunity against SARS-CoV-2 variants, SARS-CoV, and MERS-CoV. A direct comparison of the sequential with cocktail regimens indicated that the cocktail vaccination strategy induced more potent neutralizing antibodies and T-cell responses against heterotypic viruses as well as broader antibody activity against pan-β-coronaviruses. Overall, these results present a potential pan-β-coronavirus vaccine strategy for improved preparedness prior to future coronavirus threats.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Biological Products Research Institute Co., Ltd., State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, Shanghai 200052, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jialu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dongmei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Shanghai Biological Products Research Institute Co., Ltd., State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, Shanghai 200052, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiuling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Shanghai Biological Products Research Institute Co., Ltd., State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, Shanghai 200052, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2023-PT350-01</GrantID><Agency>Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences</Agency><Country /></Grant><Grant><GrantID>2021-I2M-5-005</GrantID><Agency>CAMS Innovation Fund for Medical Sciences</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000711949">Lipid Nanoparticles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="N">mRNA Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="Y">Severe acute respiratory syndrome-related coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="Y">Liposomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">broad-spectrum vaccine</Keyword><Keyword MajorTopicYN="N">cocktail immunization</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">mRNA vaccine</Keyword><Keyword MajorTopicYN="N">sequential immunization</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing financial interests/personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38543849</ArticleId><ArticleId IdType="pmc">PMC10976147</ArticleId><ArticleId IdType="doi">10.3390/v16030484</ArticleId><ArticleId IdType="pii">v16030484</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou J., Liu Z., Zhang G., Xu W., Xing L., Lu L., Wang Q., Jiang S. Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines. J. Med. Virol. 2022;95:e28172. doi: 10.1002/jmv.28172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28172</ArticleId><ArticleId IdType="pmc">PMC9538210</ArticleId><ArticleId IdType="pubmed">36161303</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto D., Sauer M.M., Czudnochowski N., Low J.S., Tortorici M.A., Housley M.P., Noack J., Walls A.C., Bowen J.E., Guarino B., et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science. 2021;373:1109–1116. doi: 10.1126/science.abj3321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj3321</ArticleId><ArticleId IdType="pmc">PMC9268357</ArticleId><ArticleId IdType="pubmed">34344823</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu H., Shuai H., Hou Y., Zhang X., Wen L., Huang X., Hu B., Yang D., Wang Y., Yoon C., et al. Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity. Sci. Adv. 2021;7:eabf8577. doi: 10.1126/sciadv.abf8577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abf8577</ArticleId><ArticleId IdType="pmc">PMC8208716</ArticleId><ArticleId IdType="pubmed">34134991</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirtipal N., Bharadwaj S., Kang S.G. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infect. Genet. Evol. 2020;85:104502. doi: 10.1016/j.meegid.2020.104502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2020.104502</ArticleId><ArticleId IdType="pmc">PMC7425554</ArticleId><ArticleId IdType="pubmed">32798769</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D.M.E., Fouchier R.A.M. Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. N. Engl. J. Med. 2012;367:1814–1820. doi: 10.1056/NEJMoa1211721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211721</ArticleId><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra H., Islam M.A., Chandran D., Emran T.B., El-Shall N.A., Al-Tawfiq J.A., Dhama K. MERS-CoV recently re-emerged in Qatar, Saudi Arabia, its feasible global health risks amid FIFA world cup 2022 and salient counteracting strategies—An update. Int. J. Surg. 2023;109:153–155. doi: 10.1097/JS9.0000000000000056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JS9.0000000000000056</ArticleId><ArticleId IdType="pmc">PMC10389596</ArticleId><ArticleId IdType="pubmed">36799834</ArticleId></ArticleIdList></Reference><Reference><Citation>Du L., He Y., Zhou Y., Liu S., Zheng B.-J., Jiang S. The spike protein of SARS-CoV—A target for vaccine and therapeutic development. Nat. Rev. Microbiol. 2009;7:226–236. doi: 10.1038/nrmicro2090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2090</ArticleId><ArticleId IdType="pmc">PMC2750777</ArticleId><ArticleId IdType="pubmed">19198616</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai W., Zheng J., Zhang X., Shi J., Wang G., Guan X., Zhu J., Perlman S., Du L. MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection. Virus Res. 2023;334:199156. doi: 10.1016/j.virusres.2023.199156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2023.199156</ArticleId><ArticleId IdType="pmc">PMC10278997</ArticleId><ArticleId IdType="pubmed">37336390</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause A.M., Marquez P., Zhang B., Myers T.R., Gee J., Su J.R., Blanc P.G., Thomas A., Thompson D., Shimabukuro T.T., et al. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥2 Years—United States, August 31–October 23, 2022. MMWR Morb. Mortal Wkly. Rep. 2022;71:1401–1406. doi: 10.15585/mmwr.mm7144a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7144a3</ArticleId><ArticleId IdType="pmc">PMC9639436</ArticleId><ArticleId IdType="pubmed">36327162</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Huang H., Yu C., Sun C., Ma J., Kong D., Lin Y., Zhao D., Zhou S., Lu J., et al. A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants. Sci. China Life Sci. 2022;66:1818–1830. doi: 10.1007/s11427-022-2207-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11427-022-2207-7</ArticleId><ArticleId IdType="pmc">PMC9811042</ArticleId><ArticleId IdType="pubmed">36598621</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert N., Tan A.T., Kunasegaran K., Tham C.Y.L., Hafezi M., Chia A., Chng M.H.Y., Lin M., Tan N., Linster M., et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457–462. doi: 10.1038/s41586-020-2550-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2550-z</ArticleId><ArticleId IdType="pubmed">32668444</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce M.G., Chen W.-H., Sankhala R.S., Hajduczki A., Thomas P.V., Choe M., Martinez E.J., Chang W.C., Peterson C.E., Morrison E.B., et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Rep. 2021;37:110143. doi: 10.1016/j.celrep.2021.110143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.110143</ArticleId><ArticleId IdType="pmc">PMC8651551</ArticleId><ArticleId IdType="pubmed">34919799</ArticleId></ArticleIdList></Reference><Reference><Citation>Woldemeskel B.A., Garliss C.C., Blankson J.N. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. J. Clin. Investig. 2021;131:e149335. doi: 10.1172/JCI149335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI149335</ArticleId><ArticleId IdType="pmc">PMC8121504</ArticleId><ArticleId IdType="pubmed">33822770</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer C.D., Scallan C.D., Kraemer Tardif L.D., Kachura M.A., Rappaport A.R., Koralek D.O., Uriel A., Gitlin L., Klein J., Davis M.J., et al. GRT-R910: A self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults. Nat. Commun. 2023;14:3274. doi: 10.1038/s41467-023-39053-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39053-9</ArticleId><ArticleId IdType="pmc">PMC10242235</ArticleId><ArticleId IdType="pubmed">37280238</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju B., Zhang Q., Wang Z., Aw Z.Q., Chen P., Zhou B., Wang R., Ge X., Lv Q., Cheng L., et al. Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants. Nat. Immunol. 2023;24:690–699. doi: 10.1038/s41590-023-01449-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01449-6</ArticleId><ArticleId IdType="pmc">PMC10063446</ArticleId><ArticleId IdType="pubmed">36914890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Sun L., Liu Z., Xing L., Zhu Y., Xu W., Xia S., Lu L., Jiang S. An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen. Emerg. Microbes Infect. 2023;12:2244084. doi: 10.1080/22221751.2023.2244084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2023.2244084</ArticleId><ArticleId IdType="pmc">PMC10424610</ArticleId><ArticleId IdType="pubmed">37534910</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen A.A., van Doremalen N., Greaney A.J., Andersen H., Sharma A., Starr T.N., Keeffe J.R., Fan C., Schulz J.E., Gnanapragasam P.N.P., et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science. 2022;377:eabq0839. doi: 10.1126/science.abq0839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq0839</ArticleId><ArticleId IdType="pmc">PMC9273039</ArticleId><ArticleId IdType="pubmed">35857620</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A.C., Fiala B., Schafer A., Wrenn S., Pham M.N., Murphy M., Tse L.V., Shehata L., O’Connor M.A., Chen C., et al. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell. 2020;183:1367–1382.e17. doi: 10.1016/j.cell.2020.10.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.043</ArticleId><ArticleId IdType="pmc">PMC7604136</ArticleId><ArticleId IdType="pubmed">33160446</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders K.O., Lee E., Parks R., Martinez D.R., Li D., Chen H., Edwards R.J., Gobeil S., Barr M., Mansouri K., et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature. 2021;594:553–559. doi: 10.1038/s41586-021-03594-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03594-0</ArticleId><ArticleId IdType="pmc">PMC8528238</ArticleId><ArticleId IdType="pubmed">33971664</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut A., Holmes E.C., O’Toole Á., Hill V., McCrone J.T., Ruis C., du Plessis L., Pybus O.G. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat. Microbiol. 2020;5:1403–1407. doi: 10.1038/s41564-020-0770-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0770-5</ArticleId><ArticleId IdType="pmc">PMC7610519</ArticleId><ArticleId IdType="pubmed">32669681</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabnis S., Kumarasinghe E.S., Salerno T., Mihai C., Ketova T., Senn J.J., Lynn A., Bulychev A., McFadyen I., Chan J., et al. A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates. Mol. Ther. 2018;26:1509–1519. doi: 10.1016/j.ymthe.2018.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2018.03.010</ArticleId><ArticleId IdType="pmc">PMC5986714</ArticleId><ArticleId IdType="pubmed">29653760</ArticleId></ArticleIdList></Reference><Reference><Citation>Gioria S., Caputo F., Urban P., Maguire C.M., Bremer-Hoffmann S., Prina-Mello A., Calzolai L., Mehn D. Are existing standard methods suitable for the evaluation of nanomedicines: Some case studies. Nanomedicine. 2018;13:539–554. doi: 10.2217/nnm-2017-0338.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nnm-2017-0338</ArticleId><ArticleId IdType="pubmed">29381129</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Guo H., Zhou P., Shi Z.-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2020;19:141–154. doi: 10.1038/s41579-020-00459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271–280.e8. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang G., Liu Z., Chen D. Human coronaviruses: Origin, host and receptor. J. Clin. Virol. 2022;155:105246. doi: 10.1016/j.jcv.2022.105246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2022.105246</ArticleId><ArticleId IdType="pmc">PMC9301904</ArticleId><ArticleId IdType="pubmed">35930858</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J.-T., Zhang J.-S., Su N., Xu J.-G., Wang N., Chen J.-T., Chen X., Liu Y.-X., Gao H., Jia Y.-P., et al. Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine. Antivir. Ther. 2007;12:1107–1114. doi: 10.1177/135965350701200702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/135965350701200702</ArticleId><ArticleId IdType="pubmed">18018769</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Wang H., Tian L., Pang Z., Yang Q., Huang T., Fan J., Song L., Tong Y., Fan H. COVID-19 vaccine development: Milestones, lessons and prospects. Signal Transduct. Target. Ther. 2022;7:146. doi: 10.1038/s41392-022-00996-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00996-y</ArticleId><ArticleId IdType="pmc">PMC9062866</ArticleId><ArticleId IdType="pubmed">35504917</ArticleId></ArticleIdList></Reference><Reference><Citation>van Doremalen N., Haddock E., Feldmann F., Meade-White K., Bushmaker T., Fischer R.J., Okumura A., Hanley P.W., Saturday G., Edwards N.J., et al. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. Sci. Adv. 2020;6:eaba8399. doi: 10.1126/sciadv.aba8399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aba8399</ArticleId><ArticleId IdType="pmc">PMC7286676</ArticleId><ArticleId IdType="pubmed">32577525</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandeel M., Morsy M.A., Abd El-Lateef H.M., Marzok M., El-Beltagi H.S., Al Khodair K.M., Albokhadaim I., Venugopala K.N. Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines. Int. Immunopharmacol. 2023;118:109998. doi: 10.1016/j.intimp.2023.109998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.109998</ArticleId><ArticleId IdType="pmc">PMC10050282</ArticleId><ArticleId IdType="pubmed">37004348</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupont L., Snell L.B., Graham C., Seow J., Merrick B., Lechmere T., Hallett S.R., Charalampous T., Alcolea-Medina A., Huettner I., et al. Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections. medRxiv. 2021 doi: 10.1101/2021.06.07.21258351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.07.21258351</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva E.S., Kohnen M., Gilson G., Staub T., Arendt V., Hilger C., Servais J.Y., Charpentier E., Domingues O., Snoeck C.J., et al. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. Int. J. Mol. Sci. 2022;23:7675. doi: 10.3390/ijms23147675.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23147675</ArticleId><ArticleId IdType="pmc">PMC9320437</ArticleId><ArticleId IdType="pubmed">35887023</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A.C., Miranda M.C., Schafer A., Pham M.N., Greaney A., Arunachalam P.S., Navarro M.J., Tortorici M.A., Rogers K., O’Connor M.A., et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell. 2021;184:5432–5447.e16. doi: 10.1016/j.cell.2021.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.09.015</ArticleId><ArticleId IdType="pmc">PMC8440233</ArticleId><ArticleId IdType="pubmed">34619077</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez D.R., Schafer A., Leist S.R., De la Cruz G., West A., Atochina-Vasserman E.N., Lindesmith L.C., Pardi N., Parks R., Barr M., et al. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science. 2021;373:991–998. doi: 10.1126/science.abi4506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abi4506</ArticleId><ArticleId IdType="pmc">PMC8899822</ArticleId><ArticleId IdType="pubmed">34214046</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Zhou J., Xu W., Deng W., Wang Y., Wang M., Wang Q., Hsieh M., Dong J., Wang X., et al. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Res. 2022;32:269–287. doi: 10.1038/s41422-022-00612-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-022-00612-2</ArticleId><ArticleId IdType="pmc">PMC8767042</ArticleId><ArticleId IdType="pubmed">35046518</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Chia W.N., Young B.E., Zhu F., Lim B.L., Sia W.R., Thein T.L., Chen M.I., Leo Y.S., Lye D.C., et al. Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. N. Engl. J. Med. 2021;385:1401–1406. doi: 10.1056/NEJMoa2108453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2108453</ArticleId><ArticleId IdType="pmc">PMC8422514</ArticleId><ArticleId IdType="pubmed">34407341</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser B.M., Sangesland M., Lam E.C., Denis K.S., Feldman J., Yousif A.S., Caradonna T.M., Kannegieter T., Balazs A.B., Schmidt A.G. Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing 1 antibodies outside the receptor binding motif. bioRxiv. 2021 doi: 10.1101/2020.12.07.415216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.07.415216</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng L., Fang Z., Renauer P.A., McNamara A., Park J.J., Lin Q., Zhou X., Dong M.B., Zhu B., Zhao H., et al. Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species. Cell Rep. 2022;40:111160. doi: 10.1016/j.celrep.2022.111160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111160</ArticleId><ArticleId IdType="pmc">PMC9294034</ArticleId><ArticleId IdType="pubmed">35921835</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez D.R., Schafer A., Gavitt T.D., Mallory M.L., Lee E., Catanzaro N.J., Chen H., Gully K., Scobey T., Korategere P., et al. Vaccine-mediated protection against Merbecovirus and Sarbecovirus challenge in mice. Cell Rep. 2023;42:113248. doi: 10.1016/j.celrep.2023.113248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.113248</ArticleId><ArticleId IdType="pmc">PMC10842144</ArticleId><ArticleId IdType="pubmed">37858337</ArticleId></ArticleIdList></Reference><Reference><Citation>de Taeye S.W., Moore J.P., Sanders R.W. HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. Trends Immunol. 2016;37:221–232. doi: 10.1016/j.it.2016.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2016.01.007</ArticleId><ArticleId IdType="pmc">PMC5454186</ArticleId><ArticleId IdType="pubmed">26869204</ArticleId></ArticleIdList></Reference><Reference><Citation>Arevalo C.P., Bolton M.J., Le Sage V., Ye N., Furey C., Muramatsu H., Alameh M.G., Pardi N., Drapeau E.M., Parkhouse K., et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science. 2022;378:899–904. doi: 10.1126/science.abm0271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm0271</ArticleId><ArticleId IdType="pmc">PMC10790309</ArticleId><ArticleId IdType="pubmed">36423275</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Zhao X., Zhou H., Zhu H., Jiang S., Wang P. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 2023;23:189–199. doi: 10.1038/s41577-022-00784-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00784-3</ArticleId><ArticleId IdType="pmc">PMC9514166</ArticleId><ArticleId IdType="pubmed">36168054</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett D.L., Jackson K.J.L., Langley D.B., Aggrawal A., Stella A.O., Johansen M.D., Balachandran H., Lenthall H., Rouet R., Walker G., et al. Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability. Immunity. 2021;54:2908–2921.e6. doi: 10.1016/j.immuni.2021.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.10.019</ArticleId><ArticleId IdType="pmc">PMC8554075</ArticleId><ArticleId IdType="pubmed">34788600</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Yisimayi A., Jian F., Song W., Xiao T., Wang L., Du S., Wang J., Li Q., Chen X., et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608:593–602. doi: 10.1038/s41586-022-04980-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04980-y</ArticleId><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>